Company Overview of Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreemen...
170 North Radnor Chester Road
Radnor, PA 19087
Founded in 2003
Key Executives for Marinus Pharmaceuticals, Inc.
Executive Chairman, Chief Executive Officer and President
Total Annual Compensation: $613.1K
Chief Financial Officer, Vice President, Treasurer and Secretary
Total Annual Compensation: $433.5K
Compensation as of Fiscal Year 2016.
Marinus Pharmaceuticals, Inc. Key Developments
Marinus Pharmaceuticals, Inc. Announces Lorianne K. Masuoka as Chief Medical Officer
Apr 11 17
Marinus Pharmaceuticals, Inc. announced that Lorianne K. Masuoka, MD has joined the company as Chief Medical Officer. As Chief Medical Officer, Dr. Masuoka will manage Marinus’ clinical programs in postpartum depression, status epilepticus and pediatric orphan indications with its positive allosteric modulator of GABA, ganaxolone.
Dr. Masuoka recently served as Chief Medical Officer of InVivo Therapeutics, Cubist Pharmaceuticals and Nektar Therapeutic where as a member of executive management she oversaw and managed teams in the areas of clinical research, drug safety, biostatistics and data management, regulatory affairs, reimbursement and clinical operations. Previously, she has held various roles of increasing responsibility at Nektar Therapeutics, FivePrime Therapeutics, and Chiron.
Marinus Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Year Ended December 31, 2016
Mar 13 17
Marinus Pharmaceuticals, Inc. reported unaudited earnings results for the year ended December 31, 2016. For the period, the company reported net losses of $28.6 million and $24.9 million for the years ended December 31, 2016 and 2015, respectively. Cash used in operating activities was $24.8 million for the year ended December 31, 2016 compared to $20.1 million for the same period a year ago. Loss from operations was $28,242,000 against $24,432,000 a year ago. Net loss per share of common stock basic and diluted was $1.47 against $1.67 a year ago.
Marinus Pharmaceuticals, Inc. Announces Preclinical Data of Neuropharmacology
Feb 14 17
Marinus Pharmaceuticals, Inc. announced the publication of preclinical data in the January issue of Neuropharmacology, showing that its positive allosteric modulator of GABAA, ganaxolone ameliorates many of the behavioral abnormalities in a mouse model of adult Angelman syndrome (AS). Evidence from experimental models suggests that AS may be associated with deficient extrasynaptic GABAA receptor function. AS is a rare neurogenetic disorder characterized by severe developmental delay, motor impairments and epilepsy. The results showed that ganaxolone-treated mice exhibited improved anxiety measures, positive motor benefits, and reduced seizures with both short- and long-term treatment. Importantly, there was no tolerance to the antiseizure efficacy of ganaxolone or to its other therapeutic actions.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|